Thank you and good morning. Thank you to ONDCP and to all the federal partners with whom we have been working on this important issue. This is a critical moment in our country. DEA’s mission is to keep American communities safe and healthy and we are in the midst of...

WASHINGTON – With the unprecedented worldwide health emergency brought on by COVID-19, last year was filled with new challenges and increased risks. While much of the world focused on combating the pandemic, DEA continued to implement initiatives to combat violent drug traffickers who were intent on flooding cities and rural...

SACRAMENTO, Calif. — On Dec. 5, a federal grand jury brought a 14-count indictment against a physician, Edmund Kemprud, of Dublin, charging him with prescribing opioids to patients outside the usual course of professional practice and not for legitimate medical purpose, U.S. Attorney McGregor W. Scott announced. According to court...

WASHINGTON – The Drug Enforcement Administration today announced action against a dangerous designer synthetic cathinone linked to 151 overdose deaths in the United States between 2015 and 2018. Published in today’s Federal Register, DEA’s action puts N-Ethylpentylone into Schedule I of the Controlled Substances Act. Schedule I substances refer to...

WASHINGTON – The Department of Justice and U.S. Drug Enforcement Administration have proposed a reduction for controlled substances that may be manufactured in the U.S. next year. Consistent with President Trump’s “Safe Prescribing Plan” that seeks to “cut nationwide opioid prescription fills by one-third within three years,” the proposal decreases...